Skip to main content
OpenTrials
Completed

NCT Number: NCT00608218

Efficacy of Ciclesonide During the Cold Season in Patients Older Than 12 Years With Persistent Asthma

The aim of the study is to evaluate the efficacy of ciclesonide in patients with persistent asthma over 3 months, especially in the cold season. Ciclesonide will be inhaled by a metered-dose inhaler. The study will provide further data on safety and tolerability of ciclesonide.

Completed

Looking for future studies?

Notify Me

Key information

Age range

12 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

"Nycomed Deutschland GmbH", Adendorf, Germany

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Main inclusion criteria:

  • History of persistent bronchial asthma

Main exclusion criteria:

  • Hypersensitive to compounds of Alvesco
  • Other criteria as defined in the Summary of Product Characteristics (Fachinformation Chapter 4.3)

Treatment and study plan

Ciclesonide

Drug

This is an observational study. Therefore, the physician decides about dosage according to individual needs.

Primary outcomes

  1. FEV1, symptom score assessment

    Time frame: within 3 months

Secondary outcomes

  1. Handling of the metered-dose inhaler, safety and tolerability

    Time frame: within 3 months

Sponsors and collaborators

Lead sponsor

AstraZeneca

Industry

Registry information

Official study title

Ciclesonide for the Therapy of Asthma During the Cold Season.

Acronym: ARTIST

Important dates

Study start
2008
Primary completion
2008
Study completion
2008
First posted
Feb 6, 2008
Registry last updated
Dec 5, 2016

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.